StreetInsider.com News Articles

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Thu, 20 Aug 2026 07:30:00 -0400

Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal

CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs

HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”) today highlights data from two scientific posters presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (SNO/ASCO) CNS Metastases Conference, held August 13–15 in Boston. One presentation featured updated pharmacokinetic (PK),

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Thu, 20 Aug 2026 07:30:00 -0400

CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Thu, 20 Aug 2026 07:30:00 -0400

CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Thu, 20 Aug 2026 07:30:00 -0400

CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Thu, 20 Aug 2026 07:30:00 -0400

CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Thu, 20 Aug 2026 07:30:00 -0400

CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Thu, 20 Aug 2026 07:30:00 -0400

CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Thu, 20 Aug 2026 07:30:00 -0400

CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Thu, 20 Aug 2026 07:30:00 -0400

CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Thu, 20 Aug 2026 07:30:00 -0400

CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs

Form 10-Q CERENOME, INC. For: Jun 30

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931824.html

Form 10-Q CERENOME, INC. For: Jun 30

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931824.html

Form 8-K CERENOME, INC. For: Aug 14

Fri, 14 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260814/26931235.html

Form 8-K CERENOME, INC. For: Aug 14

Fri, 14 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260814/26931235.html

Cerenome Reports Second Quarter 2026 Financial Results and Business Update